The comatose patient

Matthias Girke

Last update: 17.09.2015

The outward unconsciousness of the comatose patient can be accompanied by inner consciousness. For this reason, a comatose patient should be treated as if she were awake and responsive, and her being were only “veiled.” There have been various reports documented of “awake” coma patients. Through what are called event-related brain potentials (ERPs), undetected waking states have been determined in patients in a “persistent vegetative state” or in a coma. The recorded ERPs of these patients were different, for example, when they were told, “Berlin is the capital of Germany”, than when they were told, “Paris is the capital of Germany.” We must act on the assumption of the presence of undetected waking states with the possibility of reflexivity in unconscious patients.

Further studies have shown that waking states can be determined in coma patients using functional magnetic resonance imaging (fMRI). One patient in a persistent vegetative state was asked to imagine that she was playing tennis. Her fMRI showed the same pattern that was documented in the brains of healthy test subjects who are imagining that they are playing tennis.
The contrast between outer unconsciousness and a lucid inner conscious experience with independent reflective capacity is especially impressive in the case of patients with near-death experiences. These observations call into question the relationship between consciousness and the nervous system, and give evidence of conscious experiences which take place independently of the physical body.

Research news

Case series: Topical application of Viscum album extract in keratinocyte carcinomas shows remissions 
A retrospective case series examined the safety and clinical effects of topical application of 10% lipophilic Viscum album extract (VALE) in individual cases of cutaneous squamous cell carcinoma (cSCC), basal cell carcinoma (BCC) and actinic keratosis (AK). The study population consisted of 55 patients with 74 skin lesions. Risk factors, concomitant therapies and diseases, adverse drug reactions to VALE and other relevant information were documented. As a result, the clinical response rate was 78% for cSCC, 70% for BCC and 71% for AK. The complete remission rates for individual lesions were 56% for cSCC, 35% for BCC and 15% for AK. Overall, the results suggest that VALE is a safe and tolerable extract, and complete and partial remissions of ceratinocyte carcinomas were observed with its use. The article is published in Complementary Medicine Research
https://doi.org/10.1159/000537979.


Further information on Anthroposophic Medicine